Table 1.
Sample characteristics by diagnostic group
| Group |
|||
|---|---|---|---|
| CTL | GAD | GAD + UDD | |
| Demographics % (n) | |||
| Male | 40.5 (30) | 30.6 (15) | 35.3 (12) |
| Female | 59.5 (44) | 69.4 (34) | 64.7 (22) |
| African-American/black | 5.3 (4) | 5.2 (3) | 11.9 (5) |
| Asian | 7.9 (6) | 8.6 (5) | 16.7 (7) |
| Caucasian/white | 44.7 (34) | 46.6 (27) | 38.1 (16) |
| Hispanic | 5.3 (4) | – | 7.1 (3) |
| Native American | – | 1 (1.7) | – |
| Other | 3.9 (3) | 5.2 (3) | – |
| (missing or not provided) | 32.9 (25) | 32.8 (19) | 26.2 (11) |
| Age M (SD) | 26.56 (9.07) | 28.44 (9.04) | 30.75 (7.75) |
| Secondary diagnoses (n) | |||
| Attention-deficit disorder | – | 1 | – |
| Eating disorder NOS | – | 3 | 1 |
| Obsessive–compulsive disorder | – | 2 | 2 |
| Panic disorder | – | 3 | 5 |
| Post-traumatic stress disorder | – | – | 3 |
| Social anxiety disorder | – | 11 | 11 |
| Specific phobia | – | 12 | 11 |
| Medication use (n) | |||
| SSRI/SNRIs | 3 | 5 | 4 |
| Benzodiazepines | – | 1 | 1 |
| Tricyclic antidepressants | 1a | – | – |
| Hormonal birth control | 14 | 13 | 4 |
| Antihistamines and allergy | 1 | 2 | – |
| Other (e.g. thyroid, asthma medication) | 5 | 7 | 3 |
Data regarding the racial/ethnic makeup of the Kent sample was not available, so information reported (apart from the ‘missing or not provided’ category) is based on the n = 144 subsample from Yale. NOS = Not Otherwise Specified
a
Amitriptyline is also used for non-psychiatric purposes (e.g., insomnia, pain, migraine treatment) and results of our HRV analyses did not differ after excluding this individual